Evidence map›Paper›PMID 42006875›Full record

ArticleFrontiers in medicine2026

Alexa K Dowdell, Thomas R Ward, Lauren T Hamilton, Roshanthi K Weerasinghe, Erica Schnettler, Pratheesh Sathyan, Alison Roos, Josiah T Wagner, John Welle, Ryan C Meng and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alexa K DowdellEarle A. Chiles Research Institute, Portland, OR, United States.
Thomas R WardProvidence St. Joseph Health, Portland, OR, United States.
Lauren T HamiltonEarle A. Chiles Research Institute, Portland, OR, United States.
Roshanthi K WeerasingheProvidence St. Joseph Health, Portland, OR, United States.
Erica SchnettlerIllumina, Inc, San Diego, CA, United States.
Pratheesh SathyanIllumina, Inc, San Diego, CA, United States.
Alison RoosIllumina, Inc, San Diego, CA, United States.
Josiah T WagnerProvidence St. Joseph Health, Portland, OR, United States.
John WelleProvidence St. Joseph Health, Portland, OR, United States.
Ryan C MengEarle A. Chiles Research Institute, Portland, OR, United States.
Alexandra Q BartlettEarle A. Chiles Research Institute, Portland, OR, United States.
Carlo B BifulcoEarle A. Chiles Research Institute, Portland, OR, United States.
Brian D PieningEarle A. Chiles Research Institute, Portland, OR, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The use of next-generation sequencing (NGS) in clinical investigations has enabled the identification of actionable biomarkers across tumor histologies, paving the way for the development of pan-tumor therapies. Gene fusions involving Methods: In this study, we investigated the frequency of Results: Among 15,128 adult patients, CGP identified 30 pathogenic Discussion: These findings highlight the value of RNA-based NGS, particularly when used alongside DNA NGS, to provide a comprehensive assessment of

Indexed as

actionabilityfusionNTRKpan-cancerreal world evidence (RWE)

Identifiers

PMID42006875
PMCPMC13083097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.